Two dimensions in targeting HER2

Journal of Clinical Oncology

Volumn 32, Issue 19, 2014, Pages 2074-2077

  Moasser, Mark M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; PACLITAXEL; PERTUZUMAB; PROTEIN KINASE B; TRASTUZUMAB;

ADAPTIVE IMMUNITY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; DIMERIZATION; DRUG BINDING SITE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG TARGETING; ENZYME INACTIVATION; HUMAN; NEGATIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN TARGETING; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; STOMACH CANCER; TH17 CELL; TUMOR IMMUNITY;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTEIN-TYROSINE KINASES; QUINAZOLINES; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; SIGNAL TRANSDUCTION;

EID: 84905841453     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.55.7652     Document Type: Article

References (73)

1. Moasser MM: The oncogene HER2: Its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 26:6469-6487, 2007
2. Ursini-Siegel J, Schade B, Cardiff RD, et al: Insights from transgenic mouse models of ERBB2-induced breast cancer. Nat Rev Cancer 7:389-397, 2007 (Pubitemid 46652484)
3. Holbro T, Beerli RR, Maurer F, et al: The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci U S A 100:8933-8938, 2003 (Pubitemid 36899201)
4. Lee-Hoeflich ST, Crocker L, Yao E, et al: A central role for HER3 in HER2-amplified breast cancer: Implications for targeted therapy. Cancer Res 68:5878-5887, 2008
5. Vaught DB, Stanford JC, Young C, et al: HER3 is required for HER2-induced preneoplastic changes to the breast epithelium and tumor formation. Cancer Res 72:2672-2682, 2012
6. Jura N, Shan Y, Cao X, et al: Structural analysis of the catalytically inactive kinase domain of the human EGF receptor. Proc Natl Acad Sci U S A 106:21608-21613, 2009
7. Soltoff SP, Carraway KL 3rd, Prigent SA, et al: ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol Cell Biol 14:3550-3558, 1994 (Pubitemid 24160762)
8. Prigent SA, Gullick WJ: Identification of c-erbB-3 binding sites for phosphatidylinositol 3′-kinase and SHC using an EGF receptor/c-erbB-3 chimera. EMBO J 13:2831-2841, 1994
9. Shepard HM, Lewis GD, Sarup JC, et al: Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic. J Clin Immunol 11:117-127, 1991
10. Cho HS, Mason K, Ramyar KX, et al: Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421:756-760, 2003 (Pubitemid 36227628)
11. Franklin MC, Carey KD, Vajdos FF, et al: Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 5:317-328, 2004 (Pubitemid 38482068)
12. Agus DB, Akita RW, Fox WD, et al: Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2:127-137, 2002 (Pubitemid 41039113)
13. Baselga J, Gelmon KA, Verma S, et al: Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 28:1138-1144, 2010
14. Baselga J, Tripathy D, Mendelsohn J, et al: Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin Oncol 26:78-83, 1999 (Pubitemid 29411436)
15. Cortés J, Baselga J, Petrella T, et al: Pertuzumab monotherapy following trastuzumab-based treatment: Activity and tolerability in patients with advanced HER2- positive breast cancer. J Clin Oncol 27:46s, 2009 (suppl: abstr 1022)
16. Baselga J, Cameron D, Miles D, et al: Objective response rate in a phase II multicenter trial of pertuzumab (P), a HER2 dimerization inhibiting monoclonal antibody, in combination with trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC) which has progressed during treatment with T. J Clin Oncol 25:33s, 2007 (suppl: abstr 1004)
17. Rech J, Arnold D, Folprecht G, et al: A pilot study of trastuzumab (Herceptin) monotherapy in patients who progressed while on chemotherapy for metastatic or locally advanced HER2-positive gastric cancer. Ann Oncol 17, 2006 (abstr 1096P)
18. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001 (Pubitemid 32222155)
19. Baselga J, Cortés J, Kim SB, et al: Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366:109-119, 2012
20. Bang YJ, Van Cutsem E, Feyereislova A, et al: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 376:687-697, 2010
21. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672, 2005 (Pubitemid 41464705)
22. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684, 2005 (Pubitemid 41464706)
23. Gianni L, Pienkowski T, Im YH, et al: Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): A randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13:25-32, 2012
24. Cuello M, Ettenberg SA, Clark AS, et al: Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res 61:4892-4900, 2001 (Pubitemid 32691907)
25. Wang SE, Xiang B, Guix M, et al: Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab. Mol Cell Biol 28:5605-5620, 2008
26. Yakes FM, Chinratanalab W, Ritter CA, et al: Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 62:4132-4141, 2002 (Pubitemid 34791085)
27. Cai Z, Zhang G, Zhou Z, et al: Differential binding patterns of monoclonal antibody 2C4 to the ErbB3-p185her2/neu and the EGFR-p185her2/neu complexes. Oncogene 27:3870-3874, 2008 (Pubitemid 351862056)
28. Fuino L, Bali P, Wittmann S, et al: Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Mol Cancer Ther 2:971-984, 2003
29. Kataoka Y, Mukohara T, Shimada H, et al: Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines. Ann Oncol 21:255-262, 2010
30. Marches R, Uhr JW: Enhancement of the p27Kip1-mediated antiproliferative effect of trastuzumab (Herceptin) on HER2-overexpressing tumor cells. Int J Cancer 112:492-501, 2004 (Pubitemid 39390616)
31. Pickl M, Ries CH: Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab. Oncogene 28:461-468, 2009
32. Scaltriti M, Rojo F, Ocaña A, et al: Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 99:628-638, 2007 (Pubitemid 47073544)
33. Serra V, Markman B, Scaltriti M, et al: NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 68:8022-8030, 2008
34. Xia W, Liu LH, Ho P, et al: Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. Oncogene 23:646-653, 2004 (Pubitemid 38241266)
35. Yao E, Zhou W, Lee-Hoeflich ST, et al: Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab. Clin Cancer Res 15:4147-4156, 2009
36. Li B, Meng Y, Zheng L, et al: Bispecific antibody to ErbB2 overcomes trastuzumab resistance through comprehensive blockade of ErbB2 heterodimerization. Cancer Res 73:6471-6483, 2013
37. Minami T, Kijima T, Kohmo S, et al: Overcoming chemoresistance of small-cell lung cancer through step-wise HER2-targeted antibody-dependent cell-mediated cytotoxicity and VEGF-targeted antiangiogenesis. Sci Rep 3:2669, 2013
38. Scaltriti M, Eichhorn PJ, Cortés J, et al: Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. Proc Natl Acad Sci U S A 108:3761-3766, 2011
39. Tomioka H, Mukohara T, Kataoka Y, et al: Inhibition of the mTOR/S6K signal is necessary to enhance fluorouracil-induced apoptosis in gastric cancer cells with HER2 amplification. Int J Oncol 41:551-558, 2012
40. Wang YC, Morrison G, Gillihan R, et al: Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers: Role of estrogen receptor and HER2 reactivation. Breast Cancer Res 13:R121, 2011
41. Weigelt B, Lo AT, Park CC, et al: HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment. Breast Cancer Res Treat 122:35-43, 2010
42. Phillips GD, Fields CT, Li G, et al: Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: Critical role for neuregulin blockade in antitumor response to combination therapy. Clin Cancer Res 20:456-468, 2014
43. Rusnak DW, Lackey K, Affleck K, et al: The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 1:85-94, 2001
44. Wood ER, Truesdale AT, McDonald OB, et al: A unique structure for epidermal growth factor receptor bound to GW572016 (lapatinib): Relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 64:6652-6659, 2004 (Pubitemid 39297926)
45. Karaman MW, Herrgard S, Treiber DK, et al: A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26:127-132, 2008
46. Burris HA 3rd, Taylor CW, Jones SF, et al: A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies. Clin Cancer Res 15:6702-6708, 2009
47. Burstein HJ, Storniolo AM, Franco S, et al: A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Ann Oncol 19:1068-1074, 2008 (Pubitemid 351796331)
48. Toi M, Iwata H, Fujiwara Y, et al: Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: Efficacy, safety, and biomarker results from Japanese patients phase II studies. Br J Cancer 101:1676-1682, 2009
49. Blackwell KL, Burstein HJ, Storniolo AM, et al: Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 28:1124-1130, 2010
50. Iqbal S, Goldman B, Fenoglio-Preiser CM, et al: Southwest Oncology Group study S0413: A phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer. Ann Oncol 22:2610-2615, 2011
51. Hecht JR, Urba SG, Koehler M: Lapatinib monotherapy in recurrent upper gastrointestinal malignancy: Phase II efficacy and biomarker analyses. Gastrointestinal Cancers Symposium, Orlando, FL, January 25-27, 2008 (abstr 43)
52. Burstein HJ, Sun Y, Dirix LY, et al: Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol 28:1301-1307, 2010
53. Swaby R, Blackwell K, Jiang Z, et al: Neratinib in combination with trastuzumab for the treatment of advanced breast cancer: A phase I/II study. J Clin Oncol 27:42s, 2009 (suppl; abstr 1004)
54. Geyer CE, Forster J, Lindquist D, et al: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733-2743, 2006 (Pubitemid 46021510)
55. Guan Z, Xu B, DeSilvio ML, et al: Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer. J Clin Oncol 31:1947-1953, 2013
56. GlaxoSmithKline: Lapatinib clinical trial update. Press release, September 9, 2011, London, United Kingdom. http://us.gsk.com/html/media-news/ pressreleases/2011/2011-pressrelease-614856.htm
57. Goss PE, Smith IE, O'Shaughnessy J, et al: Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: A randomised, controlled, phase 3 trial. Lancet Oncol 14:88-96, 2013
58. Konecny GE, Pegram MD, Venkatesan N, et al: Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 66:1630-1639, 2006 (Pubitemid 43259947)
59. Zhang D, Pal A, Bornmann WG, et al: Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells. Mol Cancer Ther 7:1846-1850, 2008
60. Sergina NV, Rausch M, Wang D, et al: Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 445:437-441, 2007 (Pubitemid 46160912)
61. Garrett JT, Olivares MG, Rinehart C, et al: Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc Natl Acad Sci U S A 108:5021-5026, 2011
62. Amin DN, Sergina N, Ahuja D, et al: Resiliency and vulnerability in the HER2-HER3 tumorigenic driver. Sci Transl Med 2:16ra7, 2010
63. Clynes RA, Towers TL, Presta LG, et al: Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 6:443-446, 2000 (Pubitemid 30208162)
64. Fan X, Brezski RJ, Fa M, et al: A single proteolytic cleavage within the lower hinge of trastuzumab reduces immune effector function and in vivo efficacy. Breast Cancer Res 14:R116, 2012
65. Park S, Jiang Z, Mortenson ED, et al: The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 18:160-170, 2010
66. Beano A, Signorino E, Evangelista A, et al: Correlation between NK function and response to trastuzumab in metastatic breast cancer patients. J Transl Med 6:25, 2008
67. Taylor C, Hershman D, Shah N, et al: Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy. Clin Cancer Res 13:5133-5143, 2007 (Pubitemid 47502081)
68. Horlock C, Stott B, Dyson PJ, et al: The effects of trastuzumab on the CD4+CD25+FoxP3+ and CD4+IL17A+ T-cell axis in patients with breast cancer. Br J Cancer 100:1061-1067, 2009
69. Perez SA, Karamouzis MV, Skarlos DV, et al: CD4+CD25+ regulatory T-cell frequency in HER-2/neu (HER)-positive and HER-negative advancedstage breast cancer patients. Clin Cancer Res 13:2714-2721, 2007 (Pubitemid 46788040)
70. Arnould L, Gelly M, Penault-Llorca F, et al: Trastuzumab-based treatment of HER2-positive breast cancer: An antibody-dependent cellular cytotoxicity mechanism? Br J Cancer 94:259-267, 2006 (Pubitemid 43151545)
71. Capietto AH, Martinet L, Fournié JJ: Stimulated γδ T cells increase the in vivo efficacy of trastuzumab in HER-2+ breast cancer. J Immunol 187:1031-1038, 2011
72. Gennari R, Menard S, Fagnoni F, et al: Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 10:5650-5655, 2004 (Pubitemid 39180938)
73. Benavides LC, Gates JD, Carmichael MG, et al: The impact of HER2/neu expression level on response to the E75 vaccine: From U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin Cancer Res 15:2895-2904, 2009